key: cord-0015454-3icaehto
authors: Dhruva, Sanket S.
title: GLASS(Y) Half-Full: Moving Towards Greater Pragmatism in Outcome Ascertainment for Clinical Trials
date: 2021-02-04
journal: Circ Cardiovasc Qual Outcomes
DOI: 10.1161/circoutcomes.120.007690
sha: 5692e551f55af94b13d41676dbe624b3507b60fa
doc_id: 15454
cord_uid: 3icaehto

nan

The study by Leonardi et al 4 in this issue of Circulation: Cardiovascular Quality and Outcomes provides helpful information about the accuracy of end point ascertainment through reliance on investigator-reported outcomes. Within the Limus Eluted From A Durable Versus Erodable Stent Coating trial, a multicenter, international RCT comparing ticagrelor and aspirin for 1 month followed by ticagrelor alone for 23 months with standard dual antiplatelet therapy for 12 months followed by 12 months of aspirin alone, the researchers conducted the GLASSY (GLOBAL LEADERS Adjudication Sub-Study) at the top 20 enrolling sites. In GLASSY, a formal CEC adjudicated investigator-reported end points as well as various end point triggers from electronic case report forms.

Leonardi et al 4 determined that CEC adjudication was feasible for examination of 4 clinical events: myocardial infarction, bleeding, stroke, and stent thrombosis. More than 98% of the triggers (either investigator-reported or through the electronic case report form) for these events could be adjudicated. However, when using CEC adjudication as the gold standard, investigator-reported events had limited global diagnostic accuracy, ranging from 59% (95% CI, 52%-66%) for stent thrombosis to 77% (95% CI, 75%-79%) for bleeding. The inaccuracy of investigator-reported events when compared with the CEC stemmed primarily from low negative predictive values. A substantial minority, ≈18%, of the total outcome events in GLASSY were unreported by investigators and identified only through electronic case report form triggers and CEC adjudication. Positive predictive values were higher, ranging from 75% for stent thrombosis to 91% for bleeding. Overall, these results show both (1) large numbers of outcome events unreported by investigators and (2) smaller, but important, numbers of outcome events reported by investigators but that did not meet CEC criteria.

The generally weak concordance with CEC findings suggests that CEC adjudication has important benefits for improving the accuracy of RCT results over investigator-reported events for clinical end points. Specifically, the imprecision of effect estimates introduced through investigator reporting could obscure the true effect of the intervention. Trials may inaccurately meet noninferiority criteria or inaccurately fail to meet superiority criteria. A Cochrane meta-analysis of RCTs studying the benefit of adjudication committees found that treatment effect estimates assessed onsite versus by adjudication committees were nearly identical, but CECs had the greatest utility when onsite investigators were unblinded and there was a high risk of misclassification. 5 Although CECs provide a crucial role in event adjudication, the implementation of several strategies could bring greater confidence in investigator-reported event ascertainment and, therefore, support more successful pragmatic RCT designs. First, local investigators should receive additional, ongoing training and support in outcome reporting. In GLASSY, the event definitions were available in the protocol, discussed at investigator meetings, and at site initiation and then remote assistance was available through a dedicated hotline. Although these are excellent informational mechanisms, investigators across heterogeneous settings (130 sites across 18 countries in GLOBAL LEADERS) will understandably have different standards for ascertaining clinical events. A handful of meetings is insufficient to make these standards as uniform as CEC definitions. One solution would be the implementation of midstream evaluation by CECs, such as after adjudication of a prespecified number of investigator-reported outcomes. This real-time, iterative feedback could help to improve accuracy of investigator-reported outcomes over time, which would be particularly helpful over the course of a trial with 2-years follow-up like GLOBAL LEADERS and for future RCTs that use the common outcomes of myocardial infarction, stroke, and bleeding.

Such feedback, however ideal, is unlikely to be successful or well-received without the second needed strategy: additional investment in engaging clinicians and health system leadership in pragmatic trials. Overwhelmingly busy clinical schedules mean that, with the exception of some clinicians within academic centers, few can be successfully engaged in RCTs. 1 Over the past year, the massive disruptions and stresses from the coronavirus disease 2019 (COVID-19) pandemic have compounded these challenges. Therefore, clinicians need incentives for the additional time and effort required for their participation in conducting high-quality RCTs. This engagement includes clinical event ascertainment and reporting based on common definitions (as in GLOBAL LEADERS), as well as other key steps in pragmatic RCTs, such as identification of potential study patients and delivery of the study intervention. Without support to better align research with clinical care, the notoriously nonstop pressures of healthcare delivery will continue precluding meaningful clinician engagement. Therefore, the third and larger needed strategy is additional investment in the Learning Healthcare System described by the National Academy of Medicineone focused on rigorous testing (through RCTs, when possible) of clinical interventions during the course of routine care. These systems have been developed in specific locations, such as Sweden's national registries and the United Kingdom's clinical trial units, to provide the backbone for RCTs with pragmatic elements. Such an evidence generation system has been proposed in the United States by leaders of federal health and healthcare agencies. 6 Reusable clinical trial infrastructures mean that learning by local clinical investigators would carry through to future studies, thereby strengthening the ability to pragmatically ascertain clinical outcomes over time.

Fortunately, novel clinical trial efforts that seek to advance this promise of pragmatism will provide guidance about if and how to depend upon investigators in routine clinical practice for event reporting. The ADAPTABLE trial (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) relies on clinician-reported data (through a common data model, health plan, and claims data) and patientreported outcomes. 7 For studies in cancer, the minimal Common Oncology Data Elements initiative seeks to use electronic health record data for outcome ascertainment in a manner that is concordant with an electronic case report form. 8 Similar efforts in cardiovascular medicine could significantly enhance confidence in specific investigator-reported outcomes. Linkage of RCTs to administrative claims has also shown promise in establishing parameters under which routinely collected data can be used for accurate ascertainment of some clinical outcomes. 9 Finally, future efforts must place patients at the center. Patient engagement through digital health technologies holds promise in having people contribute their electronic health record, patient-reported (eg, symptoms), and patient-generated (eg, from wearable networked devices) data. 10 Geofencing data from smartphones can also provide information about hospitalizations and length of stay. 11 Triangulation of these data sources with investigator-reported events could strengthen confidence in event ascertainment.

In summary, the GLASSY investigators demonstrated that CEC adjudication significantly enhanced the quality and accuracy of outcome ascertainment compared to investigator-reported outcomes in a large, international RCT. The glass remains half-full for supporting greater pragmatism in outcome ascertainment over time through several ongoing efforts and strategies, which could herald important advances for the clinical trial enterprise-allowing more efficient generation of robust RCT evidence to guide clinical practice. 

Dr Dhruva receives research funding from the National Heart, Lung, and BloodInstitute (NHLBI, K12HL138046) of the National Institutes of Health (NIH), Food and Drug Administration, National Evaluation System for health Technology Coordinating Center (NESTcc), Greenwall Foundation, and Arnold Ventures.

Pragmatic trials

The PRECIS-2 tool: designing trials that are fit for purpose

Trends in the explanatory or pragmatic nature of cardiovascular clinical trials over 2 decades

Comparison of investigator-reported and clinical event committee-adjudicated outcome events in GLASSY

Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates

Transforming evidence generation to support health and health care decisions

Rationale and design of the aspirin dosing-a patient-centric trial assessing benefits and long-term effectiveness (ADAPTABLE) trial

The electronic health record as a clinical trials tool: opportunities and challenges

Use of administrative claims to assess outcomes and treatment effect in randomized clinical trials for transcatheter aortic valve replacement: findings from the EXTEND study

Use of mobile health applications in low-income populations: a prospective study of facilitators and barriers